Rhizen Pharmaceuticals

aka Rhizen Pharmaceuticals AG, Rhizen Pharmaceuticals SA

Rhizen Pharmaceuticals is a Swiss biotech, part of India's Incozen group, whose dual PI3K delta and gamma inhibitor tenalisib is being tested in T-cell lymphoma and breast cancer.

Rhizen Pharmaceuticals, based in Basel, discovers small molecules for cancer and immune disease. Tenalisib (RP6530) inhibits the delta and gamma isoforms of PI3K, which are enriched in lymphocytes and myeloid cells; it has been studied in relapsed T-cell lymphomas, in combination with romidepsin, and in hormone receptor-positive breast cancer. Rhizen also discovered the PI3K delta inhibitor umbralisib, later developed by TG Therapeutics.